Mood disorders dismantle more than day-to-day mood. Major depressive disorder affected an estimated 264 million people worldwide, and persistent anhedonia appears in 71% of major depressive episodes. In bipolar I mania, grandiosity shows up in 72% of acute cases, and sleep disruption affects 80% to 90% of depressed patients.
Key Takeaways
- Persistent anhedonia is a core symptom present in 71% of major depressive episodes.
- Bipolar manic episodes involve elevated mood or irritability in 89% of cases, per DSM-5 criteria.
- Suicidal ideation occurs in 50-70% of individuals with untreated depression.
- Globally, major depressive disorder affected an estimated 264 million people in 2020, representing a 28% increase since 1990.
- In the United States, the 12-month prevalence of major depressive disorder among adults aged 18 and over was 8.3% in 2021.
- Bipolar disorder has a lifetime prevalence of approximately 2.8% worldwide according to meta-analyses of epidemiological studies.
- Genetic factors account for 40-50% of the risk for bipolar disorder based on twin studies.
- Childhood maltreatment increases the risk of depression by 2.5 to 3.5 times in adulthood.
- Chronic stress from low socioeconomic status raises mood disorder risk by 1.8-fold.
- Depression causes 280 million lost workdays annually in the U.S., costing $44 billion.
- Suicide accounts for 50% of deaths in bipolar disorder, lifetime risk 15-20%.
- Untreated depression increases mortality risk by 1.6-fold from somatic diseases.
- SSRIs like fluoxetine achieve 50-65% response rate in first-line MDD treatment.
- Cognitive behavioral therapy (CBT) reduces depression symptoms by 50% in 60% of patients after 12-16 sessions.
- Lithium prophylaxis prevents manic relapses in 60-80% of bipolar patients over 1-2 years.
Sleep issues, anhedonia, and high suicide risk are common across depression and bipolar disorders worldwide.
Related reading
01 · Category
Clinical Features30 stats
01
Persistent anhedonia is a core symptom present in 71% of major depressive episodes.
02
Bipolar manic episodes involve elevated mood or irritability in 89% of cases, per DSM-5 criteria.
03
Suicidal ideation occurs in 50-70% of individuals with untreated depression.
04
Psychomotor retardation is observed in 46% of melancholic depression subtypes.
05
Grandiosity is reported in 72% of acute bipolar I manic episodes.
06
Sleep disturbance affects 80-90% of depressed patients, with early morning awakening classic.
07
Cognitive impairment in executive function persists in 40% of remitted depression cases.
08
Hypomanic symptoms like increased energy occur in 60% of bipolar II patients annually.
09
Feelings of worthlessness or excessive guilt in 58% of major depression cases.
10
Rapid cycling bipolar (4+ episodes/year) seen in 15-20% of bipolar patients.
11
Atypical depression features hypersomnia and hyperphagia in 25-40% of cases.
12
Mixed features (manic symptoms in depression) in 30% of bipolar depressed episodes.
13
Loss of interest (anhedonia) severity correlates with 65% of depression functional impairment.
14
Delusions occur in 15-20% of severe psychotic depression cases.
15
Irritability predominates in 50% of pediatric bipolar presentations vs. euphoria in adults.
16
Fatigue or loss of energy in 73% of MDD patients per STAR*D study.
17
Racing thoughts reported in 77% of manic phases.
18
Concentration difficulties in 67% of depressed adults.
19
Catatonia features in 10-15% of severe mood disorder hospitalizations.
20
Emotional numbing persists in 35% of treatment-resistant depression.
21
Increased talkativeness in 88% of hypomanic episodes.
22
Weight changes (gain/loss >5%) in 55% of depression episodes.
23
Anxiety comorbidity in 60% of bipolar disorder patients.
24
Recurrent major depression shows seasonal pattern in 10-20% of cases.
25
Psychotic features (hallucinations/delusions) in 25% of bipolar I depressions.
26
Diminished ability to think or indecisiveness in 64% per epidemiological surveys.
27
Euphoria in only 43% of youth bipolar mania vs. 70% adults.
28
Somatic complaints without medical cause in 45% of somatoform-depression overlap.
29
Prodromal symptoms precede bipolar onset by 1-2 years in 80%.
30
Melancholic features (nonreactive mood) in 25-30% of MDD.
Interpretation
Clinical Features Interpretation
These statistics paint a grimly specific portrait: depression is a thief of function and feeling, while bipolar disorder is a volatile captor of mood, but both are brutally systematic in how they dismantle a person.
02 · Category
Epidemiology30 stats
01
Globally, major depressive disorder affected an estimated 264 million people in 2020, representing a 28% increase since 1990.
02
In the United States, the 12-month prevalence of major depressive disorder among adults aged 18 and over was 8.3% in 2021.
03
Bipolar disorder has a lifetime prevalence of approximately 2.8% worldwide according to meta-analyses of epidemiological studies.
04
Among U.S. adolescents aged 12-17, 20.1% experienced a major depressive episode in the past year in 2021.
05
Dysthymia, or persistent depressive disorder, has a 12-month prevalence of 1.5% in the general U.S. adult population.
06
Women are 1.7 times more likely than men to experience major depression over their lifetime, with rates of 11.9% vs. 7.0%.
07
The incidence rate of bipolar I disorder is estimated at 0.44% per year in community samples.
08
In Europe, the pooled prevalence of any mood disorder is 14.0% based on 27 studies involving over 100,000 participants.
09
Among U.S. adults, 5.7% had bipolar disorder in the past year according to the 2021 NSDUH survey.
10
Postpartum depression affects 10-15% of new mothers worldwide within the first year after childbirth.
11
Seasonal affective disorder prevalence in the U.S. is 5% in northern states and 1.5% in southern states.
12
The global point prevalence of bipolar disorder in 2019 was 0.53%, affecting 40 million people.
13
In low- and middle-income countries, depression prevalence is 5.5% compared to 6.1% in high-income countries.
14
U.S. adults aged 18-25 had the highest past-year major depression rate at 21.0% in 2021.
15
Lifetime prevalence of any mood disorder in U.S. adults is 20.6% from the National Comorbidity Survey Replication.
16
Among children aged 3-17, 3.2% had serious mood disturbance in 2019 per NSCH data.
17
Premenstrual dysphoric disorder affects 3-8% of menstruating women.
18
In Australia, 1 in 6 people experience depression in their lifetime.
19
The age-standardized incidence rate of depressive disorders increased by 0.12% annually from 1990 to 2019 globally.
20
Hispanic adults in the U.S. have a past-year bipolar I/II prevalence of 4.2%.
21
In the UK, 17% of adults screened positive for depression during the COVID-19 pandemic in 2021.
22
Cyclothymic disorder lifetime prevalence is estimated at 0.4-1% in the general population.
23
Among U.S. college students, 44% reported feeling depressed in the past year per 2022 surveys.
24
Global disability-adjusted life years (DALYs) due to depressive disorders were 74 million in 2019.
25
Black/African American adults have a 9.3% past-year major depression rate in the U.S.
26
In Canada, 11.9% of the household population aged 15+ reported mood disorder symptoms in 2012.
27
The prevalence of mood disorders in primary care settings is 10-20%.
28
Among veterans, PTSD with major depression comorbidity affects 12%.
29
In Japan, lifetime prevalence of major depression is 7.9-15.3% varying by study.
30
U.S. rural adults have a 7.5% higher depression prevalence than urban.
Interpretation
Epidemiology Interpretation
Our global psyche is quietly fraying, with each new statistic not merely a number but a testament to the profound and widespread struggle against a tide of mood disorders that is rising across every age, gender, and geography.
03 · Category
Etiology28 stats
01
Genetic factors account for 40-50% of the risk for bipolar disorder based on twin studies.
02
Childhood maltreatment increases the risk of depression by 2.5 to 3.5 times in adulthood.
03
Chronic stress from low socioeconomic status raises mood disorder risk by 1.8-fold.
04
Family history of depression confers a 2-3 times higher risk to first-degree relatives.
05
Serotonin transporter gene (5-HTTLPR) short allele interacts with stress to increase depression risk by 2-fold.
06
Obesity (BMI >30) is associated with a 55% increased risk of developing depression.
07
Disruptions in the HPA axis contribute to 30-50% of depression cases via cortisol dysregulation.
08
Smoking increases depression risk by 1.7 times, independent of other factors.
09
Bipolar disorder has a heritability estimate of 85% from large-scale genetic studies.
10
Adverse childhood experiences (ACE score >=4) raise depression odds by 4.6 times.
11
Inflammation markers like CRP >3mg/L predict 1.5-fold higher depression incidence.
12
Sleep disturbances precede depression onset in 40% of cases longitudinally.
13
Parental divorce increases adolescent depression risk by 1.5-2 times.
14
Vitamin D deficiency (<20 ng/mL) is linked to 1.3-fold higher odds of depression.
15
Cannabis use disorder raises bipolar disorder risk by 2.8 times.
16
Female sex hormones fluctuations contribute to 20-30% higher depression rates in women.
17
Neuroticism personality trait increases depression vulnerability by 2-3 fold.
18
Lead exposure in childhood elevates mood disorder risk by 1.4 times per study.
19
Hypothyroidism doubles the risk of developing depression.
20
Early life trauma alters BDNF gene expression, increasing depression susceptibility by 40%.
21
Shift work disrupts circadian rhythms, raising depression risk by 33%.
22
Social isolation increases depression incidence by 1.9 times in longitudinal cohorts.
23
Maternal depression during pregnancy raises offspring mood disorder risk by 1.5-2.5x.
24
High caffeine intake (>400mg/day) correlates with 20% higher anxiety-depression comorbidity.
25
Genome-wide association studies identify 102 loci for bipolar disorder.
26
Rumination cognitive style mediates 50% of stress-depression relationship.
27
Traumatic brain injury increases bipolar risk by 1.6-fold.
28
Poor diet quality (high processed foods) links to 32% higher depression odds.
Interpretation
Etiology Interpretation
While my genes load the gun, it's life's myriad misfortunes—from toxic stress and trauma to sleepless nights and lonely days—that so often pull the trigger, weaving a tapestry of risk where nature and nurture are inextricably and tragically entwined.
More related reading
04 · Category
Prognosis and Burden30 stats
01
Depression causes 280 million lost workdays annually in the U.S., costing $44 billion.
02
Suicide accounts for 50% of deaths in bipolar disorder, lifetime risk 15-20%.
03
Untreated depression increases mortality risk by 1.6-fold from somatic diseases.
04
30-50% of MDD patients experience chronicity >2 years without treatment.
05
Bipolar disorder shortens life expectancy by 8-12 years on average.
06
Remission rates drop to 15% per year in treatment-resistant depression.
07
Mood disorders contribute 5.9% of global DALYs, second only to cardiovascular.
08
20% of postpartum depression cases persist beyond 1 year untreated.
09
Functional recovery lags symptom remission by 6-12 months in 50% MDD.
10
Annual U.S. healthcare costs for depression exceed $80 billion.
11
Relapse rate in bipolar is 37% within 1 year, 60% in 2 years post-mania.
12
Depression doubles risk of coronary heart disease onset.
13
70% of depressed patients have comorbid anxiety, worsening prognosis.
14
Global economic burden of depression projected at $1 trillion lost productivity yearly.
15
Suicide attempt rate in bipolar I is 25-50% lifetime.
16
Chronic depression increases dementia risk by 2-fold after age 60.
17
50% of first-episode MDD recur within 5 years without maintenance therapy.
18
Mood disorders linked to 20% higher all-cause mortality in primary care cohorts.
19
Unemployment rate among depressed adults is 3 times higher than non-depressed.
20
Bipolar II has 20% completed suicide rate, higher than bipolar I.
21
Persistent depressive disorder halves quality-adjusted life years.
22
Depression in elderly predicts 40% higher nursing home admission risk.
23
15% of severe melancholic depression untreated leads to fatal outcome.
24
Comorbid substance use disorder triples bipolar relapse rates.
25
Depression accounts for 12.2% of total years lived with disability globally.
26
25% of youth with depression develop bipolar within 5 years.
27
Lost productivity from bipolar costs U.S. $202 billion annually.
28
60% of remitters from depression relapse within 5 years despite treatment.
29
Mood disorders increase stroke risk by 45% in meta-analyses.
30
Early intervention in bipolar improves 10-year outcome in 40% more patients.
Interpretation
Prognosis and Burden Interpretation
Behind these staggering numbers lies the brutal reality that mood disorders are not just feelings but systemic health crises that dismantle lives, economies, and longevity with a cold, statistical precision.
05 · Category
Treatment30 stats
01
SSRIs like fluoxetine achieve 50-65% response rate in first-line MDD treatment.
02
Cognitive behavioral therapy (CBT) reduces depression symptoms by 50% in 60% of patients after 12-16 sessions.
03
Lithium prophylaxis prevents manic relapses in 60-80% of bipolar patients over 1-2 years.
04
ECT remission rates reach 70-90% in severe treatment-resistant depression.
05
Interpersonal therapy (IPT) shows 50% symptom reduction in 70% of MDD cases.
06
Lamotrigine maintenance reduces bipolar depression recurrence by 45%.
07
Mindfulness-based cognitive therapy (MBCT) halves relapse risk in recurrent depression.
08
SNRIs like venlafaxine have 60% response in SSRI non-responders.
09
Quetiapine augmentation improves response by 25% in unipolar depression.
10
TMS (transcranial magnetic stimulation) achieves 50% improvement in 58% of TRD patients.
11
Valproate stabilizes mood in 50% of acute mania episodes.
12
Ketamine provides rapid antidepressant effect in 70% of TRD within 24 hours.
13
Behavioral activation therapy equals antidepressants in mild-moderate depression efficacy.
14
Aripiprazole adjunctive therapy boosts remission by 25% in MDD.
15
Psilocybin-assisted therapy shows 80% reduction in depression scores at 1 week.
16
Olanzapine-fluoxetine combo remits 55% of bipolar depression.
17
Exercise (150 min/week moderate) reduces depression symptoms by 30-40%.
18
Bupropion has 59% response rate and lower sexual side effects.
19
Family-focused therapy reduces bipolar relapses by 40% over 2 years.
20
Esketamine nasal spray FDA-approved with 70% response in TRD at day 28.
21
Dialectical behavior therapy (DBT) cuts suicide attempts by 50% in BPD-comorbid mood disorders.
22
Mirtazapine improves sleep in 75% of depressed insomniacs.
23
VNS (vagus nerve stimulation) long-term response in 40-50% TRD after 2 years.
24
Omega-3 fatty acids adjunctive reduce symptoms by 20% in meta-analyses.
25
Psychoeducation lowers bipolar hospitalization by 35%.
26
Vortioxetine enhances cognition in depression with 40% improvement.
27
Light therapy remits 60% of seasonal affective disorder cases.
28
Brexpiprazole adjunct remits 30% more MDD patients than placebo.
29
rTMS protocols achieve 29% remission in MDD per meta-analysis.
30
Carbamazepine effective in 50% of lithium-resistant mania.
Interpretation
Treatment Interpretation
Looking at this medley of percentages, it becomes clear that managing mood disorders is less about finding a single magic bullet and more about arming ourselves with a whole quiver of decently effective, if imperfect, arrows.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Mood Disorder Statistics. Gitnux. https://gitnux.org/mood-disorder-statistics
MLA
Henrik Dahl. "Mood Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mood-disorder-statistics.
Chicago
Henrik Dahl. 2026. "Mood Disorder Statistics." Gitnux. https://gitnux.org/mood-disorder-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level